News Articles for PharmAust

Biotech company PharmAust has announced it will raise $10 million, alongside a $2 million share purchase plan.

Shares in Perth biotech company PharmAust rose by 14 per cent on Friday to 21 cents, following news Michael Thurn had been reappointed as the company’s managing director and chief executive officer.

Our board moves wrap includes Chris Mews, Rachel Kerr, Shelby Coleman, Hasaka Martin, Andrew Metcalfe, Brad Marwood, Jon Edwards, Bruce Garlick, Johnathon Busing, Peter Huljich, Tolga Kumova, Blagojce Pavlovski, Tony Bevan, Sergio Duchini, Sam Wright, Neville Bassett, Michael McFadyen, Su-Mei Sain, and Nick Cernotta.

Shares in Claremont-based PharmAust rose 5 per cent early on Friday morning, following news the company had received orphan drug designation for both monepantel and the treatment of motor neurone disease and amyotrophic lateral sclerosis.

Our board moves wrap includes Elizabeth Henson, Jon Coates, Shannon Robinson, Glenn Cooper, Grant Anderson, Greg Smith, Fergus Kiley, Keith Martens, Craig Burton, Peter Swiridiuk, Michael Thurn.

PharmAust's chief executive Michael Thurn has resigned from the Perth biotech company, triggering a drop in its share price.

Our board moves wrap includes Darryl Cuzzubbo, Gavin Lockyer, Colin Zhao, Ivan Cheng, Klaus Eckhof, Zane Lewis, Tom Duthy, Robert Bishop, Greg Lee, John Jetter, Shannon Robinson, Davide Bosio, David Morton, and Ray Lee.

Our board moves wrap includes Karl Page, Larry Marshall, Dino Otranto, Fiona Hick, Mark Barnaba, Michael Thurn, and Roger Aston.

PharmAust has appointed liquidators to wind-up its biotech subsidiary Epichem after it lost its lifeline contract and succumbed to cost pressures.

Helping patients by solving an unmet medical need whilst creating jobs and generating a revenue stream might seem like the ultimate win-win-win for a healthcare professional. However, getting a good idea to market means embarking on a long and winding road to commercialisation. Enter the Australian Clinical Entrepreneur Program launched recently in Perth.

ASX-listed PharmAust Ltd subsidiary Epichem OHD has hit a milestone in its development of technology to turn waste into fuel on an industrial scale, after the company completed the build of a benchtop scale reactor that will enable research, development and promotion of its potentially disruptive technology. The reactor turns biomass waste from a wide range of sources into fuels, fertiliser, agricultural growth stimulants and even ethanol.

ASX-listed biotechnology company PharmAust has filed a patent for the use of its monepantel anti-cancer drug to treat viral diseases, having previously said the drug had a positive anti-viral effect on cultured cells infected with COVID-19. The company is developing monepantel as a novel, safe and effective treatment for cancer in humans and animals and is also testing its efficacy in neurodegenerative disease.

Perth-based biotechnology company PharmAust has clinched an agreement with the Walter and Eliza Hall Institute for research into the effectiveness of its monepantel drug against a cancer-inducing virus in humans. The research raises hopes for an effective treatment for 10-to-20 million people worldwide infected with the HTLV-1 virus, which causes pulmonary disease, inflammatory disorders and, in some cases, leukaemia or lymphoma.

ASX-listed PharmAust appears to have made a breakthrough in its fight to combat canine cancer with a “phase IIb” trial of its Monepantel anti-cancer drug reportedly achieving tumour regression and increased progression-free survival in dogs. The company says the results could have significant implications for human cancer treatment and it will now fast-track to phase-three animal trials.

ASX-listed biotechnology company, PharmAust has secured Monash Health Human Research Ethics Committee approval for a Phase I clinical trial to assess the effectiveness of its monepantel product in combating motor neuron disease. Twelve trial participants will be tested in the fourth quarter this year. The trial has about A$880,000 of funding from charitable organisation, FightMND Australia.

ASX-listed PharmAust continues to receive positive news from the ongoing Phase IIb trial of its “Monepantel” anti-cancer drug trial on dogs. The clinical-stage oncology company said the interim analysis of its drug trial provided further supportive evidence of the blood plasma levels of the Monepantel drug required to suppress B-cell lymphoma growth in pet owner's dogs.

ASX-listed clinical-stage oncology company, PharmAust has pocketed $755,594 after the ATO accepted its application for a Research and Development rebate in recognition of the innovations under development by the company's wholly owned subsidiaries, Epichem and Pitney Pharmaceuticals. PharmAust said it plans to plough the cash straight back into ongoing clinical trials of its therapeutics on humans and animals.

ASX-listed pharmaceutical company, PharmAust continues to kick goals in its endeavours to develop antiviral treatment and prevention therapeutics for COVID-19. The company has once again demonstrated that its lead drug candidates monepantel and monepantel sulfone appear to show protection against cell death in non-human primate systems. Human clinical trials are now on the cards with production of the drug suitable for human consumption having already commenced.

ASX and Frankfurt Stock Exchange-listed PharmAust has unveiled encouraging initial results from the continuing phase IIb clinical trial of its anti-cancer drug, Monepantel on pet dogs suffering from B-cell lymphoma. The Perth-based company says the first five dogs who have undergone treatment with Monepantel across five participating test sites show “minimal side effects”.

ASX-listed PharmAust subsidiary, Epichem, has entered into a multi-year license agreement to harness “Oxidative Hydrothermal Dissolution” technology from IP owner, Illinois-based Thermaquatica. Epichem will research, develop and promote Thermaquatica's disruptive waste to fuels technology that uses waste and biomass as a feedstock. The company will also target government grant funding to accelerate its research and development initiative.

Pet owners have rallied to help ASX-listed PharmAust start to evaluate the effects of its newly formulated anti-cancer drug, Monepantel on dogs suffering from B-cell lymphoma in a planned phase IIb clinical trial. The Perth-based company, who hopes to further substantiate Monepantel's tumour-reduction qualities, says several hounds have already been successfully recruited and have commenced treatment with Monepantel tablets.

ASX-listed clinical-stage biotech group, PharmAust has put out a call to pet owners who have dogs with B-cell lymphoma to allow their pets to participate in a Phase IIb trial to help the company evaluate its newly formulated anti-cancer drug Monepantel. PharmAust says recent trials have shown the drug is a safe and effective treatment for dogs that have not undergone any treatment for this type of cancer.

ASX-listed clinical-stage oncology group, PharmAust has extended its pre-clinical studies collaboration with the Olivia Newton-John Cancer Research Institute as they work towards determining how effectively PharmAust's Monepantel drug combats cancer cells.

ASX-listed pharmaceutical innovator, PharmAust, will begin manufacturing Monepantel tablets for two important Phase 1 and Phase 2 human trials to study the drug's impact on Motor Neuron Disease and certain cancers. It will be the first time PharmAust has used its Monepantel drug in tablet form to investigate its anti-cancer activity in humans.

ASX-listed oncology innovator, PharmAust, has received Government ethics approval to recommence a trial treating pet dogs suffering from cancer with its oral drug, Monepantel. PharmAust previously announced the first set of trial results had exceeded expectations by demonstrating that MPL tablets can make certain cancer lesions disappear and the recommencement of the trial is the next step on the pathway to commercialisation for the biotechnology specialist.

ASX-listed clinical-stage oncology company, PharmAust, has achieved a further annual extension to its current contract with the Drugs for Neglected Diseases initiative, or “DNDi”. The extension marks the 13th year that PharmAust's wholly-owned subsidiary, Epichem, has been engaged by DNDi. The contract is expected to generate up to $1.02 million in revenue during 2021.

Votes of confidence in Perth-based clinical-stage oncology group PharmAust's cancer-fighting drugs are growing by the day as their safety profile and efficacy on cancer cells continue to be demonstrated by leading research. Latest results from the Olivia Newton-John Cancer Research Institute support previous studies that indicate non-cancer cells are not affected by Monepantel while it causes cancer cells to stop multiplying, and to self-destruct.

ASX-listed clinical-stage oncology group, PharmAust, has taken the next significant step towards establishing whether its cancer fighting drug, Monepantel, can also inhibit COVID-19. The Perth-based company has struck an agreement with an internationally renowned biomedical research university in the Netherlands that will examine the suitability of Monepantel and Monepantel Sulfone for the all-important preclinical ex-vivo stage of testing that precedes the critical clinical trials.

ASX-listed PharmAust plans to start a phase one clinical trial of its cancer fighting drug, Monepantel, next year to see if it can help patients suffering from Motor Neurone Disease. The clinical-stage oncology company was recently awarded a grant of $881,085 from FightMND that will be used to conduct the trials. Melbourne-based FightMND was co-founded by former AFL player and coach, Neale Daniher, and is the largest independent funder of MND research in Australia.

Perth based oncology company, PharmAust, has confirmed the anti-viral potential of its Monepantel drug in the fight against COVID-19 and firmed up its strategy for other potential treatments using the drug, including treating cancer in dogs and treating human neurodegenerative disease.

ASX-listed clinical-stage oncology group, PharmAust, continues to show that its cancer fighting drugs, Monepantel and Monepantel Sulfone, can have a positive, anti-viral effect on cultured cells that are infected with the Coronavirus. According to the Perth-based company, a second repeat of its in-vitro anti-viral confirmatory testing successfully demonstrated the anti-COVID-19 activity of both Monepantel and Monepantel Sulfone.

PharmAust subsidiary Epichem has entered into a joint venture deal to develop a “disruptive” waste-to-fuels technology using biomass and feedstock. Under the 50:50 agreement, medicinal and synthetic chemistry group Epichem and new JV partner Obsidian Minerals will set up the Perren company with the aim of developing and commercialising the biomass/feedstock oxidative hydrothermal dissolution chemical process that can turn waste into fuels.

PharmAust's cancer fighting drugs continue to inhibit COVID-19 in its testing of the effects of the drugs on cultured cells infected by the virus. Preliminary results from lab studies undertaken for PharmAust by the Walter and Eliza Hall Institute of Medical Research in Melbourne show the virus can be suppressed by up to about 95 per cent following treatment with the company's monepantel and monepantel sulfone products.

ASX-listed PharmAust Limited has delivered the final report on its successful Phase II clinical trial, using the Monepantel drug to treat cancer in dogs, to the US$8.8B market capped pharmaceutical giant, NYSE-listed Elanco. Under an option agreement inked two years ago with PharmAust, the animal health-focused mega-Pharma company now has six months to take up the option to licence, manufacture, and market Monepantel globally.

ASX-listed PharmAust Limited has shown that the initial successful testing of its cancer fighting drug, Monepantel, against the COVID-19 virus may not have been a fluke, with new testing showing a “remarkable” 95% suppression rate in the infectivity of the SARS-CoV- 2 virus (COVID-19) in laboratory tests by both Monepantel and Monepantel sulfone. Testing was undertaken at Walter and Eliza Hall Institute of Medical Research in Melbourne.

ASX-listed PharmAust Limited has produced some early stage positive results from laboratory testing of the effects of its anti-cancer drug, Monepantel, on the Coronavirus. The testing, which took place at the Walter and Eliza Hall Institute of Medical Research in Melbourne, showed suppression of the virus by between 50% and 95% after treatment by Pharmaust's Monepantel.

ASX-listed PharmAust Limited has chalked up a remarkable success with its rapidly developing “Monepantel” anti-cancer drug after its latest trial on man's best friend showed a significant turnaround in the health of dogs suffering from naïve B cell lymphoma. One dog achieved greater than 60 per cent reduction in tumour burden, with one of its tumours regressing completely.

Hold the whiskey and the luxury dresses, WA manufacturing has shown its dynamism by shifting to sanitiser, scrubs and masks.

ASX-listed PharmAust Limited will shortly commence laboratory testing of the effects of its anti-cancer drug, Monepantel on the Coronavirus after entering into an agreement with the Walter and Eliza Hall Institute of Medical Research in Melbourne, Victoria. The study will be overseen by the Institute's award-winning, chronic infections researcher, Professor Marc Pellegrini, with feedback expected as early as May this year.

Bentley-based manufacturer Epichem will be pumping out a new supply of hand sanitiser to cover a shortfall in the local healthcare industry.